Clinical perspectives of PSMA PET/MRI for prostate cancer

Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.

[1]  H. Jadvar.  Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[3]  W. Brenner,et al.  Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT , 2018, European Radiology.

[4]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[5]  Michael J. Zelefsky,et al.  Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI , 2015, European Radiology.

[6]  A. Kishan,et al.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning , 2017, The Journal of Nuclear Medicine.

[7]  Frederik L. Giesel,et al.  68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters , 2017, The Journal of Nuclear Medicine.

[8]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[9]  D. Collins,et al.  Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. , 2017, Radiology.

[10]  A. Kopp-Schneider,et al.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Oguz Akin,et al.  MR imaging of treated prostate cancer. , 2012, Radiology.

[12]  R. Velthoven,et al.  Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[14]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[15]  P. Carroll,et al.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience , 2017, The Journal of Nuclear Medicine.

[16]  C. Ritter,et al.  Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga‐PSMA‐positron emission tomography/computerized tomography , 2015, The Prostate.

[17]  Thomas Hambrock,et al.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging. , 2011, Radiology.

[18]  M. Roethke,et al.  PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Dora H. Tao,et al.  Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[20]  G. Cheon,et al.  Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges , 2017, Nuclear Medicine and Molecular Imaging.

[21]  B. Hadaschik,et al.  Therapy assessment in prostate cancer using choline and PSMA PET/CT , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  R. Baumann,et al.  Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT , 2017 .

[23]  L. Kong,et al.  False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature. , 2015, Oncology letters.

[24]  J. Pinski,et al.  Glucose Metabolism of Human Prostate Cancer Mouse Xenografts , 2005, Molecular imaging.

[25]  F. Mottaghy,et al.  Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  F. Mottaghy,et al.  Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges? , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Marceli de Oliveira Santos.  Estimativa 2018: Incidência de Câncer no Brasil , 2018 .

[28]  T. Wilt,et al.  Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer , 2017, The New England journal of medicine.

[29]  S. Combs,et al.  68Ga‐PSMA‐PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment , 2017, The Prostate.

[30]  M. Frydenberg,et al.  Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice , 2002, Acta oncologica.

[31]  H. Heinzer,et al.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.

[32]  Evis Sala,et al.  METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer☆ , 2017, European urology.

[33]  P. Stricker,et al.  Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET , 2017, The Journal of Nuclear Medicine.

[34]  C. Ritter,et al.  See the unseen: Mesorectal lymph node metastases in prostate cancer , 2016, The Prostate.

[35]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[36]  Clemens Decristoforo,et al.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  T. Derlin,et al.  68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer , 2017, Nuclear Medicine and Molecular Imaging.

[38]  M. Schwaiger,et al.  Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  K. Miles,et al.  Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer , 2017, European Radiology.

[40]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[41]  A. Drzezga,et al.  EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT , 2017, The Journal of Nuclear Medicine.

[42]  Steven P. Rowe,et al.  PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[43]  H. Jadvar,et al.  PSMA PET: Transformational Change in Prostate Cancer Management? , 2017, The Journal of Nuclear Medicine.

[44]  G. Jerusalem,et al.  Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology? , 2010, PET clinics.

[45]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[46]  Markus Krönke,et al.  Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68Ga-PSMA PET/CT , 2017, The Journal of Nuclear Medicine.

[47]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[48]  M. Gorin,et al.  Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. , 2017, PET clinics.

[49]  S. Larson,et al.  Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Choyke,et al.  Advancement of MR and PET/MR in Prostate Cancer. , 2016, Seminars in nuclear medicine.

[51]  S. Larson,et al.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen , 2011, Proceedings of the National Academy of Sciences.

[52]  D. Quinn,et al.  What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[53]  C. Stief,et al.  68Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer. , 2017, The Urologic clinics of North America.

[54]  M. Essler,et al.  68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer. , 2016, Clinical nuclear medicine.

[55]  N. Nickols,et al.  The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[56]  G. Cook,et al.  Imaging metastatic bone disease from carcinoma of the prostate , 2009, British Journal of Cancer.

[57]  D. Murphy,et al.  Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment , 2017, The Journal of Nuclear Medicine.

[58]  A. Oto,et al.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.

[59]  Koen Van Laere,et al.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  M. Schwaiger,et al.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. , 2016, The Journal of urology.

[61]  T. Derlin,et al.  68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer , 2016, Strahlentherapie und Onkologie.

[62]  B. Tombal,et al.  Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? , 2011, Advances in urology.

[63]  S. Kaplan,et al.  The molecular biology of prostate cancer: current understanding and clinical implications , 2017, Prostate Cancer and Prostatic Diseases.

[64]  M. Schwaiger,et al.  Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  A. Stenzinger,et al.  Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[66]  T. Eade,et al.  The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study , 2018, The Journal of Nuclear Medicine.

[67]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[68]  C. Kim,et al.  Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. , 2010, AJR. American journal of roentgenology.

[69]  W. Wadsak,et al.  68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  M. Hofman,et al.  Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. , 2017, PET clinics.

[71]  P. Choyke,et al.  Evaluation of Prostate Cancer with PET/MRI , 2016, The Journal of Nuclear Medicine.

[72]  M. Schwaiger,et al.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. , 2016, European urology.

[73]  R. Baumann,et al.  Oligometastases in prostate cancer , 2017, Strahlentherapie und Onkologie.